Current treatment of atypical hemolytic uremic syndrome - Wikidata - wikimedia - TriplyDB

Current treatment of atypical hemolytic uremic syndrome

Current treatment of atypical hemolytic uremic syndrome

http://www.wikidata.org/entity/Q27003211

about

First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients.Thrombotic Microangiopathy in a Patient Treated With Gemcitabine.Hemolytic uremic syndrome as the presenting manifestation of WT1 mutation and Denys-Drash syndrome: a case report.At the Cross Section of Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome: A Narrative Review of Differential Diagnostics and a Problematization of Nomenclature.Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab.Complement-targeted therapy: development of C5- and C5a-targeted inhibition.Advances in our Understanding of the Pathogenesis of Hemolytic Uremic Syndromes.Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation.C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome: Two Important Manifestations of Complement System Dysfunction.

P2860

Q33435451-A20C0C0F-1D71-4EC7-AB2E-4AACDFED1A0A Q33439166-7E1F4DD8-3868-4D59-8E87-6DFEBDB7409C Q33916961-9AE1859F-F6DB-4131-8E36-50CED1039C26 Q39309248-EACAF2EF-2FBA-4488-B043-26DF6F69C7B4 Q40593336-D3949FD1-9B8F-48EF-889D-BB2B756A9926 Q47155344-E8FAB2B6-B95B-46A3-8B65-283FA1B52577 Q49789113-9EDB8214-9D5A-43D8-B2FF-34975F93D2A4 Q51213973-DC0A10E1-E09A-453E-9E1E-0FACB68476C6 Q55287167-480BD682-8127-498E-944A-144B49336357

P2860

Current treatment of atypical hemolytic uremic syndrome

http://www.wikidata.org/entity/Q27003211

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Current treatment of atypical hemolytic uremic syndrome

@ast

Current treatment of atypical hemolytic uremic syndrome

@en

Current treatment of atypical hemolytic uremic syndrome

@nl

type

label

Current treatment of atypical hemolytic uremic syndrome

@ast

Current treatment of atypical hemolytic uremic syndrome

@en

Current treatment of atypical hemolytic uremic syndrome

@nl

prefLabel

Current treatment of atypical hemolytic uremic syndrome

@ast

Current treatment of atypical hemolytic uremic syndrome

@en

Current treatment of atypical hemolytic uremic syndrome

@nl

P1433

Q27003211-82ABC49B-9DB2-4B56-A643-9D7A844370DF

P1476

Q27003211-E3317DD6-4FD3-4736-B5E1-84CE1E38C434

P2093

Q27003211-0185417D-57E8-4368-A739-1E29EC1AD8C9

Q27003211-26BEA29C-9ADA-4CC2-9830-2EAE4476FE90

Q27003211-C0F0FC04-6464-46DC-85E7-080154879FAA

P2860

Q27003211-07C73959-9A5C-443B-935D-6BEF03915C55

Q27003211-104CD4A1-DE42-419E-B259-9AB818EA5D60

Q27003211-12A475C7-07F5-47E6-8A92-82D56029E800

Q27003211-12EC27BB-C35D-4729-858C-C16BC07ADD9E

Q27003211-135CF6CC-49C3-450D-BB39-0AA19A30419B

Q27003211-1C031585-5769-4166-9380-56D111443B04

Q27003211-233F8847-9C45-44FA-9566-39DA367C37E4

Q27003211-242FB5FF-864E-4CB3-9036-E36BB86AE11F

Q27003211-28986427-11C0-4C4E-9CB6-CD66D1BC3E9F

Q27003211-28C571DF-009F-4C4E-BD80-C41AF0A16686

P304

Q27003211-63B72086-0C1F-4D22-8E46-9C491B20BB66

P31

Q27003211-D633C7DF-88EA-4ACE-B8C5-6A42E84C43BA

P3181

Q27003211-6C235E51-CB8A-4286-8B76-59097B6C1ED7

P356

Q27003211-F2671F23-7C75-4463-9525-6682FA562A93

P407

Q27003211-BD0EF977-B3EF-44E7-8679-C26F572BE938

P433

Q27003211-DFEE78CE-23C1-416C-829C-B2E9410D7DD3

P478

Q27003211-70148469-AD8E-4D4F-82D6-6ABBC8A574CF

P50

Q27003211-8272ABE3-2768-4921-A2C1-698B0F35794E

P577

Q27003211-5A297983-D6CE-47F9-8853-5976063AFBB9

P698

Q27003211-45401C26-529C-42E5-96BD-893CFC260073

P932

Q27003211-B2F5B3C8-EBE5-4A81-9D0A-679CFA0EA794

P3181

P356

IRDR.2014.01001

P1433

Intractable & Rare Diseases Research

P1476

Current treatment of atypical hemolytic uremic syndrome

@en

P2093

Bernard S Kaplan

http://www.w3.org/2001/XMLSchema#string

Joann M Spinale

http://www.w3.org/2001/XMLSchema#string

Rebecca L Ruebner

http://www.w3.org/2001/XMLSchema#string

P2860

Atypical hemolytic uremic syndrome

Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome

Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy

Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype

Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura

Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome

Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome

Complement. First of two parts

Novel inborn error of folate metabolism: identification by exome capture and sequencing of mutations in the MTHFD1 gene in a single proband

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

P304

34-45

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1570803

http://www.w3.org/2001/XMLSchema#string

P356

10.5582/IRDR.2014.01001

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Lawrence Copelovitch

P577

2014-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25343125

http://www.w3.org/2001/XMLSchema#string

P932

4204535

http://www.w3.org/2001/XMLSchema#string